Flualprazolam 1mg Pellet contains flualprazolam, a benzodiazepine derivative that was first synthesized in 1976 but was never commercially marketed as a conventional pharmaceutical. The compound subsequently emerged as a designer benzodiazepine and was definitively identified in Sweden in 2018.
Product In-Stock: InStock
Flualprazolam 1mg Pellet | Noteworthy Benzodiazepine Profile
Flualprazolam 1mg Pellet contains flualprazolam, a benzodiazepine derivative that was first synthesized in 1976 but was never commercially marketed as a conventional pharmaceutical. The compound subsequently emerged as a designer benzodiazepine and was definitively identified in Sweden in 2018.
Flualprazolam can be described chemically as the 2′-fluoro derivative of alprazolam or as the fluoro analogue of triazolam in which the corresponding chlorine substitution is replaced by fluorine. Its structural relationship to these established benzodiazepines has contributed to its classification within the broader benzodiazepine family.
Flualprazolam 1mg Pellet is associated with sedative and anxiolytic pharmacological properties. Like other benzodiazepine-related compounds, its activity involves the central nervous system and may produce effects such as sedation, relaxation, and reduced anxiety.
Despite its early synthesis, flualprazolam was never developed into a widely marketed prescription medicine. Its later appearance as a designer benzodiazepine means that clinical information concerning its safety, therapeutic applications, long-term effects, and interactions remains considerably more limited than for approved benzodiazepine medications.
The compound has also attracted regulatory attention. Flualprazolam is restricted in Sweden, and in December 2019, the World Health Organization (WHO) recommended that it be considered for international control under the Convention on Psychotropic Substances.
Because Flualprazolam 1mg Pellet contains a benzodiazepine derivative with limited established clinical use, it should not be treated as equivalent to an approved alprazolam or triazolam product. Benzodiazepine-related substances can cause sedation, impaired coordination, cognitive impairment, memory problems, dependence, and withdrawal.
Combining flualprazolam with alcohol, opioids, or other central nervous system depressants may increase the risk of excessive sedation and serious adverse effects. Its regulatory status may also vary between countries, making it important to consider applicable laws and restrictions before handling or researching the compound.
Flualprazolam 1mg Pellet is therefore best described as a novel benzodiazepine research compound with a distinctive pharmacological and regulatory history rather than as an established therapeutic medication.
